787-P: Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World—Initial Results from the Association of British Clinical Diabetologists’ (ABCD) Audit
Semaglutide is the first glucagon like peptide-1 receptor agonist (GLP1-RA) available in an oral preparation. Weight and HbA1c outcomes with injectable semaglutide in the real-world are well established. The aim of this analysis is to assess weight and HbA1c response to oral semaglutide. Methods: Da...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2023-06, Vol.72 (Supplement_1), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | 1 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 72 |
| creator | CRABTREE, THOMAS S.J. ADAMSON, KAREN KRISHNASAMY, SENTHILKUMAR THIN KHINE, MAY DE, PARIJAT PETER, RAJESH RYDER, ROBERT E. |
| description | Semaglutide is the first glucagon like peptide-1 receptor agonist (GLP1-RA) available in an oral preparation. Weight and HbA1c outcomes with injectable semaglutide in the real-world are well established. The aim of this analysis is to assess weight and HbA1c response to oral semaglutide.
Methods: Data were extracted from the secure online ABCD audit tool. Individuals were included if baseline and follow-up weight and/or HbA1c data were available. Change in HbA1c, body mass index (BMI) and weight from baseline was assessed using a multivariate linear regression model and change in the numbers achieving an endpoint HbA1c≤7.5% [58mmol/mol] were assessed using Chi2 tests in Stata 16.
Results: Data were available for 350 individuals with baseline mean±SD HbA1c 9.2%±1.7 [76.6mmol/mol±18.3], weight 101.8kg±21.9, BMI 34.3kg/m2±6.9, median diabetes duration 11years (IQR 6-16) and age 59 years (IQR 51-68); 63.0% were male and 79.7% were white. Median follow-up was 0.5years (IQR 0.3-0.8). Significant reductions in HbA1c of 0.7% (95%CI 0.4, 0.9; P |
| doi_str_mv | 10.2337/db23-787-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2849359128</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2849359128</sourcerecordid><originalsourceid>FETCH-LOGICAL-c638-19e365905ca7a4de00b546b0d9ea779d04a81167b4f2904f94316ca42fdc073e3</originalsourceid><addsrcrecordid>eNo10cFOGzEQBmALgUQIvfQJRuIClRbs9Wa95hZCC0hIQTQSva289mxi5KzB9qrqLQ_RS5-i78STsATQHObyzT_SDCFfGT3NORdnpsl5JiqR3e2QEZNcZjwXv3bJiFKWZ0xIsU8OYnyklJZDjcj_LT6HK9drHxFUZ-AB7XKVYN4n7dcYYRqj11YlNPDbphXMg3LwE9dq6fpkDYLtIK0Q7lG57MEHZ142f286m-zg7jH2LkVog19v1Wea9R34Fi7C4OIKZs52Vg8Dl1Y1mLzzSxtTfNn8g-PpxezyBKa9semQ7LXKRfzy0cdk8eP7Ynad3c6vbmbT20yXvMqYRF5OJJ1oJVRhkNJmUpQNNRKVENLQQlWMlaIp2lzSopUFZ6VWRd4aTQVHPiZH77FPwT_3GFP96PvQDRvrvCokn0iWV4P69q508DEGbOunYNcq_KkZrd_-Ub_9ox5OXN_xVxhPgDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2849359128</pqid></control><display><type>article</type><title>787-P: Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World—Initial Results from the Association of British Clinical Diabetologists’ (ABCD) Audit</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>CRABTREE, THOMAS S.J. ; ADAMSON, KAREN ; KRISHNASAMY, SENTHILKUMAR ; THIN KHINE, MAY ; DE, PARIJAT ; PETER, RAJESH ; RYDER, ROBERT E.</creator><creatorcontrib>CRABTREE, THOMAS S.J. ; ADAMSON, KAREN ; KRISHNASAMY, SENTHILKUMAR ; THIN KHINE, MAY ; DE, PARIJAT ; PETER, RAJESH ; RYDER, ROBERT E.</creatorcontrib><description>Semaglutide is the first glucagon like peptide-1 receptor agonist (GLP1-RA) available in an oral preparation. Weight and HbA1c outcomes with injectable semaglutide in the real-world are well established. The aim of this analysis is to assess weight and HbA1c response to oral semaglutide.
Methods: Data were extracted from the secure online ABCD audit tool. Individuals were included if baseline and follow-up weight and/or HbA1c data were available. Change in HbA1c, body mass index (BMI) and weight from baseline was assessed using a multivariate linear regression model and change in the numbers achieving an endpoint HbA1c≤7.5% [58mmol/mol] were assessed using Chi2 tests in Stata 16.
Results: Data were available for 350 individuals with baseline mean±SD HbA1c 9.2%±1.7 [76.6mmol/mol±18.3], weight 101.8kg±21.9, BMI 34.3kg/m2±6.9, median diabetes duration 11years (IQR 6-16) and age 59 years (IQR 51-68); 63.0% were male and 79.7% were white. Median follow-up was 0.5years (IQR 0.3-0.8). Significant reductions in HbA1c of 0.7% (95%CI 0.4, 0.9; P<0.001) [7.4mmol/mol; 95%CI 4.7, 10.0; P<0.001] were observed. Weight decreased by 3.3kg (95%CI 2.3, 4.3; P<0.001) and BMI fell by 1.1kg/m2 (95%CI 0.6, 1.6; P<0.001). Twice as many people achieved a HbA1c≤7.5% at follow-up compared to baseline (28.6% [52/182] vs 14.3% [26/182]) - this change was statistically significant (P<0.001).
Conclusion: In the real-world, oral semaglutide is associated with statistically significant and clinically meaningful reductions in HbA1c, weight and BMI. The numbers achieving a HbA1c≤7.5% also increased. In the light of this, further data collection and analysis should be undertaken, including comparisons between oral and injectable GLP1-RAs and analysis of switches between them</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db23-787-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Antidiabetics ; Body mass index ; Data collection ; Diabetes mellitus ; Glucagon ; Statistical analysis ; Weight</subject><ispartof>Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1</ispartof><rights>Copyright American Diabetes Association Jun 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27928,27929</link.rule.ids></links><search><creatorcontrib>CRABTREE, THOMAS S.J.</creatorcontrib><creatorcontrib>ADAMSON, KAREN</creatorcontrib><creatorcontrib>KRISHNASAMY, SENTHILKUMAR</creatorcontrib><creatorcontrib>THIN KHINE, MAY</creatorcontrib><creatorcontrib>DE, PARIJAT</creatorcontrib><creatorcontrib>PETER, RAJESH</creatorcontrib><creatorcontrib>RYDER, ROBERT E.</creatorcontrib><title>787-P: Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World—Initial Results from the Association of British Clinical Diabetologists’ (ABCD) Audit</title><title>Diabetes (New York, N.Y.)</title><description>Semaglutide is the first glucagon like peptide-1 receptor agonist (GLP1-RA) available in an oral preparation. Weight and HbA1c outcomes with injectable semaglutide in the real-world are well established. The aim of this analysis is to assess weight and HbA1c response to oral semaglutide.
Methods: Data were extracted from the secure online ABCD audit tool. Individuals were included if baseline and follow-up weight and/or HbA1c data were available. Change in HbA1c, body mass index (BMI) and weight from baseline was assessed using a multivariate linear regression model and change in the numbers achieving an endpoint HbA1c≤7.5% [58mmol/mol] were assessed using Chi2 tests in Stata 16.
Results: Data were available for 350 individuals with baseline mean±SD HbA1c 9.2%±1.7 [76.6mmol/mol±18.3], weight 101.8kg±21.9, BMI 34.3kg/m2±6.9, median diabetes duration 11years (IQR 6-16) and age 59 years (IQR 51-68); 63.0% were male and 79.7% were white. Median follow-up was 0.5years (IQR 0.3-0.8). Significant reductions in HbA1c of 0.7% (95%CI 0.4, 0.9; P<0.001) [7.4mmol/mol; 95%CI 4.7, 10.0; P<0.001] were observed. Weight decreased by 3.3kg (95%CI 2.3, 4.3; P<0.001) and BMI fell by 1.1kg/m2 (95%CI 0.6, 1.6; P<0.001). Twice as many people achieved a HbA1c≤7.5% at follow-up compared to baseline (28.6% [52/182] vs 14.3% [26/182]) - this change was statistically significant (P<0.001).
Conclusion: In the real-world, oral semaglutide is associated with statistically significant and clinically meaningful reductions in HbA1c, weight and BMI. The numbers achieving a HbA1c≤7.5% also increased. In the light of this, further data collection and analysis should be undertaken, including comparisons between oral and injectable GLP1-RAs and analysis of switches between them</description><subject>Antidiabetics</subject><subject>Body mass index</subject><subject>Data collection</subject><subject>Diabetes mellitus</subject><subject>Glucagon</subject><subject>Statistical analysis</subject><subject>Weight</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo10cFOGzEQBmALgUQIvfQJRuIClRbs9Wa95hZCC0hIQTQSva289mxi5KzB9qrqLQ_RS5-i78STsATQHObyzT_SDCFfGT3NORdnpsl5JiqR3e2QEZNcZjwXv3bJiFKWZ0xIsU8OYnyklJZDjcj_LT6HK9drHxFUZ-AB7XKVYN4n7dcYYRqj11YlNPDbphXMg3LwE9dq6fpkDYLtIK0Q7lG57MEHZ142f286m-zg7jH2LkVog19v1Wea9R34Fi7C4OIKZs52Vg8Dl1Y1mLzzSxtTfNn8g-PpxezyBKa9semQ7LXKRfzy0cdk8eP7Ynad3c6vbmbT20yXvMqYRF5OJJ1oJVRhkNJmUpQNNRKVENLQQlWMlaIp2lzSopUFZ6VWRd4aTQVHPiZH77FPwT_3GFP96PvQDRvrvCokn0iWV4P69q508DEGbOunYNcq_KkZrd_-Ub_9ox5OXN_xVxhPgDA</recordid><startdate>20230620</startdate><enddate>20230620</enddate><creator>CRABTREE, THOMAS S.J.</creator><creator>ADAMSON, KAREN</creator><creator>KRISHNASAMY, SENTHILKUMAR</creator><creator>THIN KHINE, MAY</creator><creator>DE, PARIJAT</creator><creator>PETER, RAJESH</creator><creator>RYDER, ROBERT E.</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20230620</creationdate><title>787-P: Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World—Initial Results from the Association of British Clinical Diabetologists’ (ABCD) Audit</title><author>CRABTREE, THOMAS S.J. ; ADAMSON, KAREN ; KRISHNASAMY, SENTHILKUMAR ; THIN KHINE, MAY ; DE, PARIJAT ; PETER, RAJESH ; RYDER, ROBERT E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c638-19e365905ca7a4de00b546b0d9ea779d04a81167b4f2904f94316ca42fdc073e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antidiabetics</topic><topic>Body mass index</topic><topic>Data collection</topic><topic>Diabetes mellitus</topic><topic>Glucagon</topic><topic>Statistical analysis</topic><topic>Weight</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CRABTREE, THOMAS S.J.</creatorcontrib><creatorcontrib>ADAMSON, KAREN</creatorcontrib><creatorcontrib>KRISHNASAMY, SENTHILKUMAR</creatorcontrib><creatorcontrib>THIN KHINE, MAY</creatorcontrib><creatorcontrib>DE, PARIJAT</creatorcontrib><creatorcontrib>PETER, RAJESH</creatorcontrib><creatorcontrib>RYDER, ROBERT E.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CRABTREE, THOMAS S.J.</au><au>ADAMSON, KAREN</au><au>KRISHNASAMY, SENTHILKUMAR</au><au>THIN KHINE, MAY</au><au>DE, PARIJAT</au><au>PETER, RAJESH</au><au>RYDER, ROBERT E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>787-P: Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World—Initial Results from the Association of British Clinical Diabetologists’ (ABCD) Audit</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2023-06-20</date><risdate>2023</risdate><volume>72</volume><issue>Supplement_1</issue><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Semaglutide is the first glucagon like peptide-1 receptor agonist (GLP1-RA) available in an oral preparation. Weight and HbA1c outcomes with injectable semaglutide in the real-world are well established. The aim of this analysis is to assess weight and HbA1c response to oral semaglutide.
Methods: Data were extracted from the secure online ABCD audit tool. Individuals were included if baseline and follow-up weight and/or HbA1c data were available. Change in HbA1c, body mass index (BMI) and weight from baseline was assessed using a multivariate linear regression model and change in the numbers achieving an endpoint HbA1c≤7.5% [58mmol/mol] were assessed using Chi2 tests in Stata 16.
Results: Data were available for 350 individuals with baseline mean±SD HbA1c 9.2%±1.7 [76.6mmol/mol±18.3], weight 101.8kg±21.9, BMI 34.3kg/m2±6.9, median diabetes duration 11years (IQR 6-16) and age 59 years (IQR 51-68); 63.0% were male and 79.7% were white. Median follow-up was 0.5years (IQR 0.3-0.8). Significant reductions in HbA1c of 0.7% (95%CI 0.4, 0.9; P<0.001) [7.4mmol/mol; 95%CI 4.7, 10.0; P<0.001] were observed. Weight decreased by 3.3kg (95%CI 2.3, 4.3; P<0.001) and BMI fell by 1.1kg/m2 (95%CI 0.6, 1.6; P<0.001). Twice as many people achieved a HbA1c≤7.5% at follow-up compared to baseline (28.6% [52/182] vs 14.3% [26/182]) - this change was statistically significant (P<0.001).
Conclusion: In the real-world, oral semaglutide is associated with statistically significant and clinically meaningful reductions in HbA1c, weight and BMI. The numbers achieving a HbA1c≤7.5% also increased. In the light of this, further data collection and analysis should be undertaken, including comparisons between oral and injectable GLP1-RAs and analysis of switches between them</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db23-787-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2849359128 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antidiabetics Body mass index Data collection Diabetes mellitus Glucagon Statistical analysis Weight |
| title | 787-P: Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World—Initial Results from the Association of British Clinical Diabetologists’ (ABCD) Audit |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T21%3A02%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=787-P:%20Glucose%20and%20Weight%20Outcomes%20Associated%20with%20Oral%20Semaglutide%20in%20the%20Real-World%E2%80%94Initial%20Results%20from%20the%20Association%20of%20British%20Clinical%20Diabetologists%E2%80%99%20(ABCD)%20Audit&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=CRABTREE,%20THOMAS%20S.J.&rft.date=2023-06-20&rft.volume=72&rft.issue=Supplement_1&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db23-787-P&rft_dat=%3Cproquest_cross%3E2849359128%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2849359128&rft_id=info:pmid/&rfr_iscdi=true |